The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Moderna starts Phase 1 trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 4, 11:17 AM EDT

Moderna starts Phase 1 trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus

The trial is designed to assess safety and immune responses for Moderna’s next-generation mRNA vaccine candidate against a rare Ebola virus strain, with the early study taking place in Canada.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna has begun a Phase 1 clinical trial of mRNA-1469, an investigational vaccine intended to protect against Bundibugyo ebolavirus, the company said in connection with a newly initiated early-stage study.

Phase 1 trials are the first step in human testing for an experimental medicine. At this stage, the primary focus is typically whether the product appears safe and whether it can generate a measurable immune response, rather than proving efficacy against infection.

According to the report, Moderna’s Phase 1 program for mRNA-1469 is being conducted in Canada. The company said it will evaluate safety and immune response, targeting a strain of Ebola virus disease for which no licensed vaccines are indicated, highlighting the need it sees for additional options in rare or underserved outbreaks.

The candidate is part of Moderna’s broader work using messenger RNA, or mRNA, technology, where genetic instructions delivered in a vaccine are designed to prompt the body to produce viral proteins and train the immune system. In early clinical research, regulators and companies generally look for immune markers that suggest the approach is working as intended.

The report also referenced an expanded collaboration in which the trial is being carried out. Moderna did not provide, in the available posting, additional operational details such as trial leadership, timelines, or the scope of the collaboration, beyond indicating it is part of a wider effort.

Moderna’s move comes as vaccine developers continue to test whether mRNA platforms can be rapidly adapted to different viral threats, including pathogens that are less common but can still cause severe outbreaks. For companies like Moderna, the ability to pursue multiple candidates across infectious diseases is also a way to diversify clinical pipelines beyond its core respiratory and oncology focus.

Still, the market implications of this announcement depend heavily on outcomes that are not yet disclosed. The available report does not specify expected enrollment, dosing regimen, study endpoints in detail, or any interim readouts for the trial, all of which will determine how quickly investors and clinicians can judge the program’s prospects.

What to watch next is whether Moderna will publish additional trial information, including the number of participants, dosing schedule, and immune-response data as the study progresses, and whether it can translate early safety and immunogenicity indicates into larger studies.

Why It Matters

  • Starting a Phase 1 trial is an early but important milestone that can position mRNA-1469 for subsequent efficacy-focused studies if safety and immune indicates are supportive.
  • Because the target strain is one for which no licensed vaccines are indicated, successful early results could expand the set of tools available during future outbreaks.
  • The choice of Canada for the Phase 1 program suggests the study could be part of broader multinational infectious-disease research capacity, though details were not disclosed.
  • The lack of trial design specifics in the announcement means near-term expectations will hinge on what Moderna reports later, including dosing and immunogenicity outcomes.

Sources

Key Facts

  • Moderna initiated a Phase 1 clinical trial of mRNA-1469.
  • mRNA-1469 is an investigational vaccine candidate targeting Bundibugyo ebolavirus.
  • The Phase 1 study is designed to evaluate safety and immune response.
  • The trial is being conducted in Canada, according to the report.
  • The company said the vaccine targets a strain of Ebola virus disease for which no licensed vaccines are indicated.
  • The announcement referenced an expanded collaboration, but did not provide additional collaboration specifics in the available posting.

Healthcare Related

Moderna starts Phase 1 trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus | The Apex Times